WO2023029210A1 - Agoniste de pp2a et composé pour purger et/ou dissoudre des cellules vieillissantes et/ou pour inhiber le vieillissement cellulaire, destinés à être utilisés dans le traitement d'un trouble mental - Google Patents

Agoniste de pp2a et composé pour purger et/ou dissoudre des cellules vieillissantes et/ou pour inhiber le vieillissement cellulaire, destinés à être utilisés dans le traitement d'un trouble mental Download PDF

Info

Publication number
WO2023029210A1
WO2023029210A1 PCT/CN2021/129503 CN2021129503W WO2023029210A1 WO 2023029210 A1 WO2023029210 A1 WO 2023029210A1 CN 2021129503 W CN2021129503 W CN 2021129503W WO 2023029210 A1 WO2023029210 A1 WO 2023029210A1
Authority
WO
WIPO (PCT)
Prior art keywords
pp2a
ppp2r2c
disorders
activity
expression
Prior art date
Application number
PCT/CN2021/129503
Other languages
English (en)
Chinese (zh)
Inventor
叶静
G埃里克
陆一鸣
陈科桦
王波
邢骏
应亦林
梁惠欣
Original Assignee
上海交通大学医学院附属瑞金医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202111023485.2A external-priority patent/CN113616795B/zh
Priority claimed from CN202111012917.XA external-priority patent/CN113694071A/zh
Application filed by 上海交通大学医学院附属瑞金医院 filed Critical 上海交通大学医学院附属瑞金医院
Publication of WO2023029210A1 publication Critical patent/WO2023029210A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

L'invention concerne une application d'un agoniste de PP2A ou d'un composé pour purger et/ou dissoudre des cellules vieillissantes et/ou pour inhiber le vieillissement cellulaire pendant la préparation d'un médicament destiné à prévenir et à traiter des troubles mentaux provoqués par un vieillissement normal. Le trouble mental est choisi parmi les troubles cognitifs, les troubles affectifs et/ou les troubles du comportement et l'agoniste de PP2A est le MPH, le DT-061 ou le FTY720. Le composé pour purger et/ou dissoudre les cellules vieillissantes et/ou pour inhiber le vieillissement cellulaire est choisi parmi ABT263, les composés qui induisent une augmentation de l'activité et/ou de l'expression de PP2A, les composés qui induisent une diminution de l'activité et/ou de l'expression de p53 et les composés qui induisent une diminution de l'activité et/ou de l'expression de p21.
PCT/CN2021/129503 2021-08-31 2021-11-09 Agoniste de pp2a et composé pour purger et/ou dissoudre des cellules vieillissantes et/ou pour inhiber le vieillissement cellulaire, destinés à être utilisés dans le traitement d'un trouble mental WO2023029210A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202111023485.2A CN113616795B (zh) 2021-08-31 2021-08-31 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
CN202111023485.2 2021-08-31
CN202111012917.X 2021-08-31
CN202111012917.XA CN113694071A (zh) 2021-08-31 2021-08-31 清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍

Publications (1)

Publication Number Publication Date
WO2023029210A1 true WO2023029210A1 (fr) 2023-03-09

Family

ID=85410805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/129503 WO2023029210A1 (fr) 2021-08-31 2021-11-09 Agoniste de pp2a et composé pour purger et/ou dissoudre des cellules vieillissantes et/ou pour inhiber le vieillissement cellulaire, destinés à être utilisés dans le traitement d'un trouble mental

Country Status (1)

Country Link
WO (1) WO2023029210A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113616795A (zh) * 2021-08-31 2021-11-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101269024A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸哌醋甲酯缓释滴丸及其制备方法
CN101478977A (zh) * 2006-03-29 2009-07-08 维拉科治疗学控股有限公司 神经变性疾病的治疗
CN103893182A (zh) * 2014-03-27 2014-07-02 中国药科大学 一类set蛋白小分子抑制剂及其用途
CN104146991A (zh) * 2014-04-04 2014-11-19 施福东 芬戈莫德及其结构类似物用于制备治疗脑梗死药物的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101478977A (zh) * 2006-03-29 2009-07-08 维拉科治疗学控股有限公司 神经变性疾病的治疗
CN101269024A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸哌醋甲酯缓释滴丸及其制备方法
CN103893182A (zh) * 2014-03-27 2014-07-02 中国药科大学 一类set蛋白小分子抑制剂及其用途
CN104146991A (zh) * 2014-04-04 2014-11-19 施福东 芬戈莫德及其结构类似物用于制备治疗脑梗死药物的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Modern Nursing of Mental Disorders", 31 October 2010, SCIENCE AND TECHNOLOGY LITERATURE PUBLISHING HOUSE, CN, ISBN: 978-7-5023-6726-8, article WU, JIANHONG ET AL.: "Causes and Classification of Mental Disorders", pages: 11, XP009544246 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113616795A (zh) * 2021-08-31 2021-11-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍

Similar Documents

Publication Publication Date Title
Yamada et al. Sensory experience remodels genome architecture in neural circuit to drive motor learning
Van Eldik et al. The roles of inflammation and immune mechanisms in Alzheimer's disease
Krebs et al. The Sac1 Domain of SYNJ 1 Identified Mutated in a Family with Early‐Onset Progressive P arkinsonism with Generalized Seizures
George et al. The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons
Qin et al. Cross-talk between KLF4 and STAT3 regulates axon regeneration
Sadikovic et al. Mutation update for UBE 3 A variants in Angelman syndrome
Sherpa et al. Retinal regeneration is facilitated by the presence of surviving neurons
Werner et al. Loss of TMEM 106B potentiates lysosomal and FTLD‐like pathology in progranulin‐deficient mice
KR20110014183A (ko) 학습 및 기억을 개선시키기 위한 화합물
Begemann et al. New insights into the clinical and molecular spectrum of the novel CYFIP2-related neurodevelopmental disorder and impairment of the WRC-mediated actin dynamics
Bedont et al. An LHX1-regulated transcriptional network controls sleep/wake coupling and thermal resistance of the central circadian clockworks
Bolger The PDE4 cAMP-specific phosphodiesterases: Targets for drugs with antidepressant and memory-enhancing action
Li et al. Silencing of the Drosophila ortholog of SOX5 leads to abnormal neuronal development and behavioral impairment
Meng et al. Tat-haFGF14–154 upregulates ADAM10 to attenuate the Alzheimer phenotype of APP/PS1 mice through the PI3K-CREB-IRE1α/XBP1 pathway
Mroske et al. Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalities
Di Fonzo et al. Lower motor neuron disease with respiratory failure caused by a novel MAPT mutation
US20200222410A1 (en) Nucleocytoplasmic regulator of autophagy-associated transcription factors
Quach et al. Intellectual disability: dendritic anomalies and emerging genetic perspectives
WO2023029210A1 (fr) Agoniste de pp2a et composé pour purger et/ou dissoudre des cellules vieillissantes et/ou pour inhiber le vieillissement cellulaire, destinés à être utilisés dans le traitement d'un trouble mental
Wang et al. Glutaminase C overexpression in the brain induces learning deficits, synaptic dysfunctions, and neuroinflammation in mice
Gaik et al. Functional divergence of the two Elongator subcomplexes during neurodevelopment
KR20150058292A (ko) 뇌기능 향상용 조성물
Yang et al. A missense mutation in Pitx2 leads to early-onset glaucoma via NRF2-YAP1 axis
CN113616795B (zh) Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
Arbeille et al. Brain Tumor promotes axon growth across the midline through interactions with the microtubule stabilizing protein Apc2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21955739

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE